|
WuXi PharmaTech Co., Ltd. Named
A Red Herring 100 Asia Company Shanghai, China 12 September 2005 "We are very pleased to be selected by Red Herring as one of the top 100 private companies in Asia,'' commented Dr. Ge Li, founder and CEO of WuXi PharmaTech, during the conference. "The award is not only a recognition of our achievement and unique business model, but also an encouragement for us to build WuXi PharmaTech into a world-class company." During the past few months, Red Herring's editorial staff rigorously evaluated more than 500 private companies through a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development. The decision to award WuXi PharmaTech a ''100 Asia Company'' reflects that the company's leading position in the pharmaceutical R&D service industry has been recognized throughout Asia and beyond. WuXi PharmaTech as well as other award winners presented their business models, strategies and visions at the Red Herring 100 Asia Conference that took place on September 5-7 at the Shangri-La Hotel in Shanghai, China. About the Red Herring 100 Asia Conference Red Herring 100 Asia Conference is an invitation-only event for
CEOs, select senior executives, and Venture Capitalists. Red Herring
100 Asia will bring together executives from mostly private companies.
These executives will be joined by senior executives from public
companies and Venture Capitalists. Red Herring is the weekly magazine technology entrepreneurs, investors and industry observers read to stay ahead of the curve and to be better informed about the global marketplace. Red Herring covers technology, innovation, financial strategies, important personalities and trends that are transforming the world of business with unique insight, opinion and forward-looking analysis. Readers turn to Red Herring for knowledge to make strategic decisions, build companies and create a competitive advantage for their businesses. Red Herring articles, blogs, research and event information can be found online at http://www.redherring.com . About WuXi PharmaTech Shanghai-based WuXi PharmaTech Co., Ltd. offers global pharmaceutical/ bio-pharmaceutical companies diverse outsourcing services in combinatorial, medicinal, synthetic chemistry and manufacturing. Importantly, it also allows them to take full advantage of the lower research costs in China. WuXi PharmaTech's rapidly expanding line of services ranges from early stage discovery chemistry through lead optimization chemistry, all the way to process research & development and bulk manufacture of active pharmaceutical ingredients. With the addition of a new GMP plant at Jinshan in Shanghai, WuXi PharmaTech has further increased its bulk production capacity to meet rapidly growing customer demand. WuXi PharmaTech's strong capabilities and impressive track record enable the company to provide a broad spectrum of integrated development services from milligram to metric ton scaled active pharmaceutical ingredients, intermediates and raw materials. Currently, WuXi PharmaTech's client list includes over 60 leading drug discovery companies covering a majority of the world's largest pharmaceutical companies.
For more information, please contact: David Yin |
All rights reserved. A Member of the United Overseas Bank Group